Drugs for inhibiting benign prostatic hyperplasia prepared from methylnephrine, capsaicin, and 6-gingerol and their applications
The combination of methylnephrine, capsaicin, and 6-gingerol solves the problem of significant side effects in existing drug treatments for benign prostatic hyperplasia, achieving effective inhibition of prostatic hyperplasia and improvement of urinary dysfunction, thus enhancing patients' quality of life.
Patent Information
- Application Number
- CN202111470728.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-03
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2041-12-03
AI Technical Summary
Existing drug treatments for benign prostatic hyperplasia have significant side effects and are not effective in reducing urinary obstruction, especially in improving symptoms of androgen imbalance.
A combination of methylnephrine, capsaicin, and 6-gingerol is used as a drug to inhibit benign prostatic hyperplasia. It relieves the symptoms of benign prostatic hyperplasia by inhibiting 5α-reductase, reducing inflammation, and improving local microcirculation.
It significantly inhibits prostate cell proliferation, reduces prostate volume, improves urinary disorders, enhances quality of life, and reduces drug side effects.
Smart Images

Figure CN114042068B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to a drug for inhibiting benign prostatic hyperplasia prepared from methyl lotusine, capsaicin, and 6-gingerol, and its application. Background Technology
[0002] Benign prostatic hyperplasia (BPH) is a common male urinary tract disease characterized by hyperplasia of the prostate gland and smooth muscle. This leads to urethral compression, causing urinary retention and urinary tract infections. It commonly affects men over 50 years of age, and its incidence is increasing annually with the aging population. BPH is related to androgen imbalance; androgens induce prostatic hyperplasia through androgen receptors and interference signaling pathways.
[0003] Clinically, surgical and drug treatments are used to treat symptoms caused by benign prostatic hyperplasia (BPH). Drug treatment aims to specifically relax the smooth muscle of the prostate and reduce its volume. Alpha-receptor blockers reduce urinary obstruction by blocking sympathetic nerve excitation, causing prostate smooth muscle contraction, but they are prone to causing hypotension as a side effect. 5α-reductase inhibitors block the conversion of androgens to dihydroandrogens, thus reducing prostate enlargement.
[0004] In modern pharmacological research, traditional Chinese medicine (TCM) formulas used for prostate issues primarily utilize the active ingredients of the medicinal materials. These TCM formulas inhibit prostate cell proliferation by interfering with signaling pathways. However, research in this area is limited, and few therapeutic drugs have been developed. Therefore, this invention aims to reduce the significant side effects of existing oral medications for benign prostatic hyperplasia (BPH) and to alleviate urinary obstruction caused by BPH, thereby providing a new treatment option. Specifically, it addresses symptoms such as androgen imbalance in patients with chronic BPH, thereby improving their quality of life. Summary of the Invention
[0005] To address the aforementioned technical problems, this invention provides a drug for inhibiting benign prostatic hyperplasia prepared from methylnephrine, capsaicin, and 6-gingerol, and its application.
[0006] The purpose of this invention is to provide a drug for inhibiting benign prostatic hyperplasia prepared from capsaicin, methyl lotusine, and 6-gingerol, wherein the drug for inhibiting benign prostatic hyperplasia comprises one or more of capsaicin, methyl lotusine, and 6-gingerol.
[0007] Preferably, in the above-mentioned drugs, when the benign prostatic hyperplasia treatment drug is a combination of capsaicin and methylcasulin and acts on cells, the molar ratio of capsaicin to methylcasulin is 1:1 to 10; preferably, the molar ratio of capsaicin to methylcasulin is 1:10.
[0008] When the benign prostatic hyperplasia treatment drug is a combination of capsaicin and methylnephrine and is used on animals, the mass ratio of capsaicin to methylnephrine is 5:1.
[0009] When the benign prostatic hyperplasia treatment drug is a combination of 6-gingerol and methylcaternine and acts on cells, the molar ratio of 6-gingerol to methylcaternine is 1:1 to 10; preferably, the molar ratio of 6-gingerol to methylcaternine is 1:10.
[0010] When the benign prostatic hyperplasia treatment drug is a combination of 6-gingerol and methylnephrine and is used on animals, the mass ratio of 6-gingerol to methylnephrine is 5:1.
[0011] The present invention also provides the use of capsaicin, methyl lotusine, and 6-gingerol in the preparation of the aforementioned drug for inhibiting benign prostatic hyperplasia.
[0012] Preferably, in the above-mentioned uses, the drug for inhibiting benign prostatic hyperplasia is used to prepare an inhibitor of human prostatic epithelial cells and normal human prostatic stromal cells.
[0013] Preferably, in the above-mentioned uses, the drug for inhibiting benign prostatic hyperplasia is formulated into a pharmaceutically permissible dosage form, wherein the dosage form is a tablet, granule, powder, oral liquid, or capsule.
[0014] Preferably, in the above-mentioned uses, the concentrations of capsaicin, methyl sennae, and 6-gingerol in the drug for inhibiting benign prostatic hyperplasia are all 10–100 μM.
[0015] Preferably, in the above-mentioned uses, when capsaicin and methyl basidine are combined, the concentrations of capsaicin and methyl basidine are 10 μM and 100 μM, respectively, or 10 μM and 10 μM, respectively.
[0016] Preferably, in the above-mentioned uses, when 6-gingerol and methyl lotusine are combined, the concentrations of 6-gingerol and methyl lotusine are 10 μM and 100 μM, respectively, or 10 μM and 10 μM, respectively.
[0017] Preferably, in the above-described uses, the drug for inhibiting benign prostatic hyperplasia is used to prepare a drug for treating benign prostatic hyperplasia in men or male mammals.
[0018] Preferably, in the above-mentioned uses, the male mammal is a mouse, and the dosages of capsaicin, methyl stigmine, and 6-gingerol used in mice are 10 mg / kg body weight, 2 mg / kg body weight, and 10 mg / kg body weight, respectively.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] This invention treats prostate diseases by inhibiting benign prostatic hyperplasia (BPH), reducing inflammation, and improving local microcirculation. Capsaicin, one of the active ingredients in chili peppers, possesses pharmacological effects such as analgesia, antipruritic properties, antioxidant activity, anticancer activity, anti-proliferative activity, anti-inflammatory effects, and anti-lipid peroxidation. Research in this invention shows that a 100 μM capsaicin concentration at 48°C inhibits the growth of prostate epithelial cells by 46%, and capsaicin also exhibits anti-proliferative effects against various cancer cells.
[0021] The lotus seed heart is the green embryo of the mature seed of the lotus plant (Nelumbo nucifera), a member of the Nymphaeaceae family. Its extracts include lotusine, isoligusine, methyl lotusine, nuciferine, pronuciferine, hyperoside, and rutin. Methyl lotusine is one of the active ingredients extracted from the green embryo of the mature seed of the lotus plant (Nelumbo nucifera), possessing pharmacological effects such as antiarrhythmia, antihypertensive, antiplatelet aggregation, antioxidant, anti-inflammatory, and anti-proliferative effects. Research in this invention indicates that methyl lotusine can act as a 5α-reductase inhibitor, thereby inhibiting benign prostatic hyperplasia / enlargement.
[0022] Ginger extract is an extract from the fresh rhizomes of ginger, a plant belonging to the genus Zingiber in the family Zingiberaceae. It contains gingerol, gingerene, bisabolene, gingerol, etc. 6-Gingerol is one of the active ingredients extracted from ginger and has antioxidant, lipid-lowering, anti-inflammatory, and anti-proliferative pharmacological effects.
[0023] In this invention, methyl lotusine, capsaicin, and 6-gingerol are 5α-reductase inhibitors and drugs that inhibit cell proliferation. The three can be used as drugs, health foods, or food additives to relieve symptoms of benign prostatic hyperplasia / enlargement. Attached Figure Description
[0024] Figure 1 The expression of 5α-reductase and PSA protein in human prostate epithelial cells after 24 hours of treatment with different concentrations of compounds, as described in this invention. Detailed Implementation
[0025] To enable those skilled in the art to better understand and implement the technical solutions of the present invention, the present invention will be further described below in conjunction with specific embodiments and accompanying drawings.
[0026] Experimental Example 1: Anti-prostate cell proliferation
[0027] The purpose of this experiment was to verify, through cell experiments, that capsaicin (10 μM, 100 μM), methylcaenine (10 μM, 100 μM), and 6-gingerol (10 μM, 100 μM) have anti-prostate cell proliferation effects. All drugs were dissolved in dimethyl sulfoxide (DMSO) solution and added to the culture medium. The DMSO concentration was less than 0.1%, v / v. Human prostate epithelial cell line LNCaP and normal human prostate stromal cells WPMY-1 were cultured in 96-well plates with appropriate cell culture medium and incubated at 37°C and 5% CO2 for approximately 48 hours. Drugs were added after the cells had adhered and grown to the culture plates. LNCaP cells were incubated in RPMI-1640 medium, and WPMY-1 cells were incubated in DMEM medium.
[0028] The drug addition experiment was divided into 9 groups: (1) control group, containing only culture medium and corresponding cells, without adding any drugs; (2) capsaicin, with two final concentrations of 10 μM and 100 μM based on the volume of culture medium; (3) methyl basilicon group, with two final concentrations of 10 μM and 100 μM based on the volume of culture medium; (4) 6-gingerol group, with two final concentrations of 10 μM and 100 μM based on the volume of culture medium; (5) high concentration methyl basilicon combined with capsaicin group, with the final concentrations of the two drugs set at 100 μM and 100 μM based on the volume of culture medium. 10 μM; (6) Low concentration of methylcaesin combined with capsaicin group, the final concentrations of the two were set at 10 μM and 10 μM respectively based on the volume of the culture medium; (7) High concentration of methylcaesin combined with 6-gingerol group, the final concentrations of the two were set at 100 μM and 10 μM respectively based on the volume of the culture medium; (8) Low concentration of methylcaesin combined with 6-gingerol group, the final concentrations of the two were set at 10 μM and 10 μM respectively based on the volume of the culture medium; (9) Positive control group finasteride (Shanghai Aladdin Biochemical Technology Co., Ltd.), the two experiments were set at 10 μM and 100 μM respectively based on the volume of the culture medium. It should be noted that when adding the above drugs, the stock solution should first be prepared to a concentration equivalent to more than 1000 times the final concentration, and then the amount of stock solution added should be calculated according to the final concentration, and the stock solution should be added to the culture medium to avoid the phenomenon of solvent poisoning of cells.
[0029] After 48 hours of incubation, the cells were washed with PBS (pH 7.4, 2 mM potassium dihydrogen phosphate, 8 mM disodium hydrogen phosphate, 136 mM sodium chloride, 2.6 mM potassium chloride), then the medium was replaced with fresh medium. 10 μL of LTT (5 mg / ml) was added to each well, and the cells were incubated at 37°C in a 5% CO2 incubator for 4 hours. After incubation, the liquid in the wells was removed, and 100 μL of dimethyl sulfoxide was added to dissolve the purple crystals. The liquid in each well was mixed thoroughly, and the samples were placed at room temperature for 20 minutes. The absorbance at 570 nm was measured, and cell viability was calculated.
[0030] Cell viability = (absorbance of experimental group - absorbance of control group) / (absorbance of control group) × 100%.
[0031] The cell activity calculation results are shown in Table 1. The experimental data in Table 1 are expressed as mean ± standard deviation. Statistical analysis of the experimental results was performed, and P < 0.05 was considered statistically significant. The results in Table 1 indicate that capsaicin, methyl lotusine, 6-gingerol, and their combinations all have significant anti-proliferative effects on prostate epithelial cells and glandular stromal cells.
[0032] Table 1 Cell viability assay values
[0033]
[0034] Note: * indicates P<0.05 compared with the control group.
[0035] Experiment Example 2: Anti-androgen-induced prostate cell proliferation
[0036] The purpose of this experiment was to verify, through cell experiments, that capsaicin (10 μM, 100 μM), methylcaine (10 μM, 100 μM), and 6-gingerol (10 μM, 100 μM) have anti-prostate cell proliferation effects. All drugs were dissolved in dimethyl sulfoxide (DMSO) solution (concentration less than 0.1%, v / v) and added to the culture medium. Human prostate epithelial cell line LNCaP and normal human prostate stromal cells WPMY-1 were cultured in 96-well plates with appropriate cell culture medium and incubated at 37°C with 5% CO2 for approximately 48 hours. Drugs were added after the cells had adhered and grown in the culture dish. LNCaP cells were incubated in RPMI-1640 medium, and WPMY-1 cells were incubated in DMEM medium. It should be noted that the above drugs were first prepared to a concentration at least 1000 times the final concentration, and then the amount of stock solution added was calculated according to the final concentration before being added to the culture medium to avoid solvent poisoning of cells.
[0037] The drug addition experiment was divided into 14 groups: (1) control group, containing only culture medium and corresponding cells, without adding any drugs; (2) testosterone group, with the final drug concentration set at 1 μM based on the volume of culture medium; (3) testosterone combined with low-concentration capsaicin group, with the final drug concentrations set at 1 μM and 10 μM based on the volume of culture medium, respectively; (4) testosterone combined with high-concentration capsaicin group, with the final drug concentrations set at 1 μM and 100 μM based on the volume of culture medium, respectively; (5) testosterone combined with low-concentration methylnephrine group, (6) The final drug concentrations based on culture medium volume were 1 μM and 10 μM, respectively; (7) The final drug concentrations based on culture medium volume were 1 μM and 100 μM, respectively; (8) The final drug concentrations based on culture medium volume were 1 μM and 100 μM, respectively; (9) The final drug concentrations based on culture medium volume were 1 μM and 10 μM, respectively; (10) The final drug concentrations based on culture medium volume were 1 μM and 100 μM, respectively; (11) The final drug concentrations based on culture medium volume were 1 μM and 100 μM, respectively; (12) The final drug concentrations based on culture medium volume were 1 μM and 100 μM, respectively; (13) The final drug concentrations based on culture medium volume were 1 μM and 100 μM, respectively; (14) The final drug concentrations based on culture medium volume were 1 μM and 100 μM, respectively; (15) The final drug concentrations based on culture medium volume were 1 μM and 100 μM, respectively; (16) The final drug concentrations based on culture medium volume were 1 μM and 100 μM, respectively; (17) The final drug concentrations based on culture medium volume were 1 μM and 100 μM, respectively; (18) The final drug concentrations based on culture medium volume were 1 μM and 100 μM, respectively; (19) The final drug concentrations based on culture medium volume were 1 μM and 100 μM, respectively; (10 ... (10) The testosterone combined with low concentration of methylcaesin and capsaicin groups, with final drug concentrations of 1 μM, 100 μM, and 10 μM based on culture medium volume; (11) The testosterone combined with high concentration of methylcaesin and 6-gingerol groups, with final drug concentrations of 1 μM, 100 μM, and 10 μM based on culture medium volume; (12) The testosterone combined with low concentration of methylcaesin and capsaicin groups, with final drug concentrations of 1 μM, 100 μM, and 10 μM based on culture medium volume; (13) Positive control group: Testosterone combined with low concentration finasteride (Shanghai Aladdin Biochemical Technology Co., Ltd.) group, the final drug concentrations were set at 1 μM, 10 μM and 10 μM respectively based on the culture medium volume; (14) Positive control group: Testosterone combined with high concentration finasteride (Shanghai Aladdin Biochemical Technology Co., Ltd.) group, the drug concentrations were set at 1 μM and 100 μM respectively based on the culture medium volume. It should be noted that the above drugs were first prepared into a stock solution with a concentration equivalent to more than 1000 times the final concentration before being added to the culture medium to avoid the phenomenon of solvent poisoning of cells.
[0038] After 48 hours of incubation, the cells were washed with PBS (pH 7.4, 2 mM potassium dihydrogen phosphate, 8 mM disodium hydrogen phosphate, 136 mM sodium chloride, 2.6 mM potassium chloride), then the medium was replaced with fresh medium. 10 μL of LTT (5 mg / ml) was added to each well, and the cells were incubated at 37°C in a 5% CO2 incubator for 4 hours. After incubation, the liquid in the wells was removed, and 100 μL of dimethyl sulfoxide was added to dissolve the purple crystals. The liquid in each well was mixed thoroughly, and the samples were placed at room temperature for 20 minutes. The absorbance at 570 nm was measured, and cell viability was calculated.
[0039] Cell viability = (absorbance of experimental group - absorbance of control group) / (absorbance of control group) × 100%.
[0040] The cell activity calculation results are shown in Table 2. The experimental data in Table 2 are expressed as mean ± standard deviation. Statistical analysis was performed on the experimental results, with P < 0.05 considered statistically significant. The results in Table 2 indicate that capsaicin, methyl lotusine, 6-gingerol, and their combinations all have significant anti-proliferative effects on prostate epithelial cells and glandular stromal cells.
[0041] Table 2 Cell viability measurements
[0042]
[0043] Note: * indicates P<0.05 compared with the control group. # indicates P<0.05 compared with the testosterone group.
[0044] Experimental Example 3: Anti-androgen-induced expression of 5α-reductase and PSA protein in prostate epithelial cells
[0045] In benign prostatic hyperplasia (BPH), 5α-reductase converts testosterone into the more potent dihydrotestosterone (DHT). Effectively reducing 5α-reductase expression can inhibit prostate cell proliferation. Following the experimental method in Example 1, capsaicin (10 μM, 100 μM), methyl lotusine (10 μM, 100 μM), 6-shogaol (10 μM, 100 μM), and methyl lotusine (100 μM) were combined with 6-shogaol (100 μM) and capsaicin (100 μM) to treat LNCaP cells. After 24 hours, cell proteins were extracted, and the expression levels of 5α-reductase and PSA proteins were detected to evaluate the effect of the compounds in inhibiting androgen-induced prostate cell proliferation by regulating the expression of these two proteins.
[0046] Figure 1 This image shows the protein expression levels of 5α-reductase and PSA protein in prostate epithelial cells after 24 hours of treatment with different concentrations of compounds. β-actin was used as an internal control. Figure 1 The results showed that methyl lotusine (10, 100 μM), 6-gingerol (10, 100 μM), and capsaicin (10, 100 μM) inhibited prostate 5α-reductase activity, thereby reducing PSA expression and exhibiting anti-proliferative effects.
[0047] Example 4: Animal Experiments on Benign Prostatic Hyperplasia
[0048] Animal and reagent preparation: For this experiment, 42 healthy male mice were purchased, all approximately 6-7 weeks old and weighing between 20-30g. After purchase, they were quarantined and kept for 1 week. The environment for keeping the male mice was set at 23±1℃ with a 12h / 12h day-night cycle. All of these male mice were able to eat and drink on their own.
[0049] On the other hand, a 10 mg / kg finasteride reagent (Shanghai Aladdin Biochemical Technology Co., Ltd.) was prepared. Corn oil was used as the solvent in the preparation of the finasteride reagent. The corn oil, a pharmaceutical excipient, was purchased from Xi'an Yuelai Pharmaceutical Technology Co., Ltd.
[0050] Grouping: Mice were randomly divided into 7 groups, with 6 mice in each group. (1) Carrier group, with 0.2 mL of corn oil as an additive; (2) Model group, i.e., model mice constructed by the following method; (3) Capsaicin group, with 10 mg / kg capsaicin added; (4) Methylsinine group, with 2 mg / kg methylsinine added; (5) 6-Gingerol group, with 10 mg / kg 6-gingerol added; (6) Compound group, with 10 mg / kg capsaicin + 2 mg / kg methylsinine added; or a combination of 2 mg / kg methylsinine + 10 mg / kg 6-gingerol added; (7) Positive control group, with 10 mg / kg finasteride added.
[0051] Note that "mg / kg" in the above grouping refers to the amount added per kilogram of mouse body weight.
[0052] Experimental Experiment: Mice were intramuscularly injected with a 7.5 mg / kg concentration of testosterone propionate solution (Shanghai Aladdin Biochemical Technology Co., Ltd.), 150 μL of testosterone propionate solution once daily, and administered orally via a feeder for two weeks to induce benign prostatic hyperplasia (BPH), thus obtaining a mouse model. After euthanasia, blood samples were collected from the heart. Before analysis, the blood was clotted and centrifuged at 3000g for 10 min to obtain serum, which was stored at -20℃. The prostate-specific antigen (PSA) content in the serum was detected using a prostate-specific antigen (PSA) kit (Jingmei ELSIA kit). The prostate of the mice was removed, and adjacent blood vessels and connective tissue were removed. The prostate of the control group, which underwent sham surgery, was removed in the same manner. The prostate index was calculated as the proportion of the total weight of the prostate to the total body weight: Prostate Index = (Total prostate weight / Total body weight) × 100%, and the results are shown in Tables 3-4. The data in Tables 3 and 4 show that testosterone propionate significantly increased prostate wet weight, prostate index, and PSA, thus demonstrating BPH. The use of methylnephrine (2 mg / kg), 6-gingerol (10 mg / kg), and capsaicin (10 mg / kg) as single or combined drugs effectively reduced and promoted prostate wet weight, prostate index, and PSA. The results indicate that methylnephrine, 6-gingerol, and capsaicin have anti-prostate hyperplasia effects.
[0053] Table 3. Effects of single and combined administration of methylnephrine, 6-gingerol, and capsaicin on serum PSA in mice.
[0054] Group PSA (ng / mL) vector group 1978.10±293.705# Model group: Testosterone propionate 7.5 mg / kg 2642.42±107.14* Methylnephrine 2mg / kg 2332.88±38.01*# Capsaicin 10mg / kg 2412.22±119.77*# 6-Gingerol 10 mg / kg 2318.27±268.58*# Methylnephrine 2 mg / kg + 6-gingerol 10 mg / kg 2059±123.66# Methylnephrine 2mg / kg + Capsicum 10mg / kg 1983.5±53.51# Finasteride 10 mg / kg 2342.99±219.98*#
[0055] Note: * indicates P<0.05 compared with the vector group, # indicates P<0.05 compared with the model group.
[0056] Table 4. Effects of single and combined administration of methylnemenine, 6-gingerol, and capsaicin on wet weight of mouse prostate.
[0057]
[0058]
[0059] Note: * indicates P<0.05 compared with the vector group, # indicates P<0.05 compared with the testosterone propionate group.
[0060] It should be noted that when numerical ranges are involved in this invention, it should be understood that both endpoints of each numerical range and any value between the two endpoints can be selected. Since the steps and methods used are the same as in the embodiments, preferred embodiments are described here to avoid redundancy. Although preferred embodiments of the invention have been described, those skilled in the art, once they understand the basic inventive concept, can make other changes and modifications to these embodiments. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments as well as all changes and modifications falling within the scope of this invention.
[0061] Obviously, those skilled in the art can make various modifications and variations to this invention without departing from its spirit and scope. Therefore, if these modifications and variations fall within the scope of the claims of this invention and their equivalents, this invention also intends to include these modifications and variations.
Claims
1. The use of capsaicin, methyl lotusine, and 6-gingerol in the preparation of drugs for inhibiting benign prostatic hyperplasia, characterized in that, The drug for inhibiting benign prostatic hyperplasia is a combination of capsaicin and methyl lotusine, or a combination of 6-gingerol and methyl lotusine; When the drug for inhibiting benign prostatic hyperplasia is a combination of capsaicin and methylcasulin and is administered to animals, the mass ratio of capsaicin to methylcasulin is 5:
1. When the drug for inhibiting benign prostatic hyperplasia is a combination of 6-gingerol and methylnephrine and is used on animals, the mass ratio of 6-gingerol to methylnephrine is 5:
1.
2. The use according to claim 1, characterized in that, The drug for inhibiting benign prostatic hyperplasia is formulated into a pharmaceutically permissible dosage form, such as tablets, granules, powders, oral liquids, or capsules.
3. The use according to claim 2, characterized in that, The drug for inhibiting benign prostatic hyperplasia is used to prepare an anti-proliferative drug for benign prostatic hyperplasia in men or male mammals.
Citation Information
Patent Citations
Lotus plumule and new application of extractive thereof
CN101862374A
Application of lotus plumule active alkaloid in preparation of prostate drugs
CN104856995A
Application of 6-gingerol in preparation of medicines for treating and preventing prostate cancer and resisting prostate cancer metastasis
CN113546065A
Therapeutic agent for chronic prostatitis, prostatomegaly, hemorrhoids and erection failure utilizing capsaicin
JP2001288077A
